Stable Isotope Labeled Compounds

Stable Isotope Labeled Compounds

Global Stable Isotope Labeled Compounds Market to Reach $365.2 Million by 2027

In the changed post COVID-19 business landscape, the global market for Stable Isotope Labeled Compounds estimated at US$282.6 Million in the year 2020, is projected to reach a revised size of US$365.2 Million by 2027, growing at a CAGR of 3.7% over the analysis period 2020-2027. Deuterium, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$149.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oxygen-18 segment is readjusted to a revised 3.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $110.7 Million, While China is Forecast to Grow at 5.8% CAGR

The Stable Isotope Labeled Compounds market in the U.S. is estimated at US$110.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.2 Million by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.Carbon-13 Segment to Record 2.7% CAGR

In the global Carbon-13 segment, USA, Canada, Japan, China and Europe will drive the 2.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$43.3 Million in the year 2020 will reach a projected size of US$51.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 73 Featured) -

  • 3M Company
  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories, Inc.
  • Chemtos
  • ISOFLEX
  • IsoSciences
  • Isotope JSC
  • Medical Isotopes, Inc.
  • Merck KGaA
  • Omicron Biochemicals, Inc.
  • Pepscan
  • PerkinElmer Inc.
  • The State Atomic Energy Corporation ROSATOM
  • Trace Sciences International
  • Urenco Stable Isotopes
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 Pandemic and Looming Global Recession
Year 2021 in Review and Near-term Outlook
Prolonged Pandemic, Ukraine-Russia Conflict and Ensuing Economic Disruptions Impact Growth Outlook
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
COVID-19 Creates Supply Chain Hiccups in the Medical Isotope Market
An Introduction to Stable Isotope Labeled Compounds
Advantages of Stable Isotope Labeling
Radioactive versus Stable Isotopes
Global Market Prospects & Outlook
Developed Regions Lead, Developing Economies to Fuel Long-term Growth
Competition
EXHIBIT 2: Stable Isotope Labeled Compounds – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche for Players Worldwide in 2022 (E)
World Brands
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Sustained Increase in Research Activities in Pharma and Biotech Sectors Augurs Well for the Market
EXHIBIT 3: Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025
EXHIBIT 4: R&D Spending as % of Revenues in Select Leading Pharmaceutical Companies (2021)
EXHIBIT 5: R&D Spending (in US$ Billion) of Select Leading Biotechnology Companies for 2020
Numerous Benefits of Stable Isotope Labelling in Biochemistry Research Propels Market Prospects
Focus on Proteomics Research Presents Growth Opportunities for Stable Isotope Labeled Compounds
EXHIBIT 6: Global Proteomics Market Revenues (in US$ Million) by Geographic Region/Country for 2020 and 2027
Proteomics Emerges as an Important Research Tool in Battle against COVID-19
Pressing Need for COVID-19 Diagnostics & Therapeutics Accentuates Dynamic Role of Proteomics
Gaining Insights into COVID-19 & Drug Discovery with Proteomics
Proteomics to Enable Potent Antiviral Agents & Better Vaccines against COVID-19
Rising Prevalence of Cancer Worldwide Drives Market Growth
EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 8: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
EXHIBIT 9: Number of New Cancer Cases and Deaths (in Million) by Region for 2020
Rising Adoption of PET Scans for Disease Staging to Support Market Prospects
Role of Stable Isotopes in Nuclear Industry & Status of Nuclear Reactors Drives Demand for Stable Isotopes
EXHIBIT 10: Global Electricity Production Breakdown by Source
EXHIBIT 11: World Installed Nuclear Power Generation Capacity (in GW) for 2020, 2030, 2040 and 2050
Rising Importance of Stable Isotopes Human Nutritional Studies
Pharmacokinetic and Metabolic Fate of Drugs: Better Understood with Isotopic Labeling of Metabolites
Advancements in Deuterium-Labeled Compounds Synthesis
Research Study Investigates Metagenomes’ Genetic Capacity to Translate into Production of VOCs of Interest
Chemical Tagging Stable Isotope Products for Chemical Labeling
Stable Isotope Studies Aid in Integration of Non-essential Amino Acids in Pea Aphids
Using Stable Isotopes to Measure Denitrification Rates in Soil
Use of Stable Isotopically Labeled Benzene to Evaluate Environmental Exposures
Stable Isotope Assisted Technique (LC-MS–Based) Offers Better Metabolites Characterization: A Brief Review
Growing Role of Stable Isotopes in Animal Migration Research
Recent Labelling Advancements in Organic Molecules
Creation of Stable Isotope Labeled Internal Standards
Mass Spec Internal Standards: Comparing Different Isotopic Labels
Use of Stable Labeled Compounds in the form of Internal Standards
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Stable Isotope Labeled Compounds Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
TABLE 2: World Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 3: World Historic Review for Stable Isotope Labeled Compounds by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 4: World 15-Year Perspective for Stable Isotope Labeled Compounds by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
TABLE 5: World Recent Past, Current & Future Analysis for Deuterium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 6: World Historic Review for Deuterium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 7: World 15-Year Perspective for Deuterium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 8: World Recent Past, Current & Future Analysis for Oxygen-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 9: World Historic Review for Oxygen-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 10: World 15-Year Perspective for Oxygen-18 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 11: World Recent Past, Current & Future Analysis for Carbon-13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 12: World Historic Review for Carbon-13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 13: World 15-Year Perspective for Carbon-13 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 14: World Recent Past, Current & Future Analysis for Nitrogen-15 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 15: World Historic Review for Nitrogen-15 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 16: World 15-Year Perspective for Nitrogen-15 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 21: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 22: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 25: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 27: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 28: World 15-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Stable Isotope Labeled Compounds Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
Market Analytics
TABLE 32: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 33: USA Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 34: USA 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 35: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 36: USA Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 37: USA 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
CANADA
Stable Isotope Labeled Compounds Market Presence - Strong/Active/Niche - Key Competitors in the Canada for 2022 (E)
Market Analytics
TABLE 38: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 39: Canada Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 40: Canada 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 41: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 42: Canada Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 43: Canada 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
JAPAN
TABLE 44: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 45: Japan Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 46: Japan 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 47: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 48: Japan Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 49: Japan 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
CHINA
Stable Isotope Labeled Compounds Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Market Analytics
TABLE 50: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 51: China Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 52: China 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 53: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 54: China Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 55: China 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
EUROPE
Stable Isotope Labeled Compounds Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Market Analytics
TABLE 56: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 57: Europe Historic Review for Stable Isotope Labeled Compounds by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 58: Europe 15-Year Perspective for Stable Isotope Labeled Compounds by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 59: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 60: Europe Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 61: Europe 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 62: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 63: Europe Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 64: Europe 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
FRANCE
TABLE 65: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 66: France Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 67: France 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 68: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 69: France Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 70: France 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
GERMANY
TABLE 71: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 72: Germany Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 73: Germany 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 74: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 75: Germany Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 76: Germany 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
ITALY
TABLE 77: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 78: Italy Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 79: Italy 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 80: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 81: Italy Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 82: Italy 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
UNITED KINGDOM
TABLE 83: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 84: UK Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 85: UK 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 86: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 87: UK Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 88: UK 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
SPAIN
TABLE 89: Spain Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 90: Spain Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 91: Spain 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 92: Spain Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 93: Spain Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 94: Spain 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
RUSSIA
TABLE 95: Russia Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 96: Russia Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 97: Russia 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 98: Russia Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 99: Russia Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 100: Russia 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 102: Rest of Europe Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 103: Rest of Europe 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 105: Rest of Europe Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 106: Rest of Europe 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Stable Isotope Labeled Compounds Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Market Analytics
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Stable Isotope Labeled Compounds by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Stable Isotope Labeled Compounds by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 112: Asia-Pacific 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 114: Asia-Pacific Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 115: Asia-Pacific 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
AUSTRALIA
TABLE 116: Australia Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 117: Australia Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 118: Australia 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 119: Australia Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 120: Australia Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 121: Australia 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
INDIA
TABLE 122: India Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 123: India Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 124: India 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 125: India Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 126: India Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 127: India 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
SOUTH KOREA
TABLE 128: South Korea Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 129: South Korea Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 130: South Korea 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 131: South Korea Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 132: South Korea Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 133: South Korea 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 138: Rest of Asia-Pacific Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
LATIN AMERICA
TABLE 140: Latin America Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 141: Latin America Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 143: Latin America Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 144: Latin America Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 145: Latin America 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
MIDDLE EAST
TABLE 146: Middle East Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 147: Middle East Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 148: Middle East 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 149: Middle East Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 150: Middle East Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 151: Middle East 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
AFRICA
TABLE 152: Africa Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 153: Africa Historic Review for Stable Isotope Labeled Compounds by Type - Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 154: Africa 15-Year Perspective for Stable Isotope Labeled Compounds by Type - Percentage Breakdown of Value Sales for Deuterium, Oxygen-18, Carbon-13, Nitrogen-15 and Other Types for the Years 2012, 2021 & 2027
TABLE 155: Africa Recent Past, Current & Future Analysis for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 156: Africa Historic Review for Stable Isotope Labeled Compounds by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 157: Africa 15-Year Perspective for Stable Isotope Labeled Compounds by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 73

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings